You searched for
Category:
#ActionOverWords
Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
03/04/2024
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
18/03/2024
Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22/09/2022
Chiesi tracks actions taken for a healthier, more sustainable future
14/07/2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02/05/2022
Chiesi Group calls for #ActionOverWords in the fight against climate change
10/05/2021
Chiesi launches “The Art of Caring”, a journey in search of the link between Parma, officinal treatments and pharmaceutics
17/11/2020
Chiesi Farmaceutici changes statute to become “Benefit Corporation”.
04/02/2019
TRIBUTE study shows superiority of Chiesi's Trimbow® (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro® (indacaterol/glycopyrronium) in reducing COPD exacerbations1
07/09/2017
For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study.
04/04/2017
The Italian Prime Minister Matteo Renzi, has visited Chiesi Farmaceutici Research Center in Parma
08/11/2016
An extrafine ICS/LABA combination decreases COPD exacerbations more than
17/05/2016